群英荟萃，智慧闪耀。肿瘤领域年度盛会2025美国临床肿瘤学会（ASCO 2025）年会即将于2025年5月30日~6月3日在美国芝加哥举行。
近日，ASCO官网公布了摘要题目及讲者信息。【肿瘤资讯】特别整理
全体大会（Plenary Session）、口头摘要专场（Oral Abstract Session）、口头摘要速递专场（Rapid Oral Abstract Session）、临床科学研讨会（Clinical Science Symposium）的肺癌领域研究，与读者分享。
口头摘要专场（Oral Abstract Session）
转移性非小细胞肺癌
摘要号: 8500
英文标题：First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study.
中文标题：adagrasib（ADA）联合帕博利珠单抗（PEMBRO）作为晚期/转移性 KRAS G12C突变NSCLC患者的一线治疗：KRYSTAL-7研究2期部分的结果
讲者：Pasi A. Jänne, PhD | Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute
摘要号: 8501
英文标题：TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC).
中文标题：TROPION-Lung02：Dato-DXd联合帕博利珠单抗±铂类化疗（Pt-CT）作为晚期非小细胞肺癌（aNSCLC）的一线（1L）治疗
讲者：Benjamin Philip Levy, MD, FASCO | Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine
摘要号: LBA8502
英文标题：CAMPASS: Benmelstobart in combination with anlotinib vs pembrolizumab in the first-line treatment of advanced non-small cell lung cancer (aNSCLC): A randomized, single-blind, multicenter phase 3 study.
中文标题：CAMPASS：贝莫苏拜单抗联合安罗替尼对比帕博利珠单抗一线治疗晚期非小细胞肺癌(aNSCLC)：一项随机、单盲、多中心3期研究
讲者：上海市胸科医院 韩宝惠
摘要号: 8503
英文标题：Efficacy of zipalertinib in NSCLC patients with EGFR exon 20 insertion mutations who received prior platinum-based chemotherapy with or without amivantamab.
中文标题：zipalertinib在既往接受过含铂化疗（无论是否接受过埃万妥单抗治疗）的 EGFR外显子 20 插入突变非小细胞肺癌（NSCLC）患者中的疗效
讲者：Helena Alexandra Yu, MD | Memorial Sloan Kettering Cancer Center
摘要号: 8504
英文标题：SOHO-01: Safety and efficacy of BAY 2927088 in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC) who were pretreated but naïve to HER2-targeted therapy or had not received any treatment for advanced disease.
中文标题：SOHO-01：BAY 2927088 用于既往接受过治疗但未接受HER2靶向治疗或未接受过任何治疗的晚期HER2突变NSCLC患者的安全性和有效性研究
讲者：香港中文大学 Herbert H. Loong
摘要号: LBA8505
英文标题：Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET-amplification (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study.
中文标题：赛沃替尼联合奥希替尼对比化疗用于EGFR-TKI治疗进展后EGFR突变伴MET扩增的晚期非小细胞肺癌患者：来自3期随机SACHI研究结果
讲者：上海市胸科医院 陆舜
摘要号: 8506
英文标题：Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study.
中文标题：Patritumab deruxtecan (HER3-DXd) 用于接受第三代EGFR-TKI治疗后耐药的EGFR突变晚期非小细胞肺癌 (NSCLC) 患者：3期HERTHENA-Lung 02研究
讲者：香港中文大学 莫树锦
摘要号: 8507
英文标题：Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study.
中文标题：芦康沙妥珠单抗（sac-TMT）用于既往接受过治疗的晚期EGFR突变非小细胞肺癌患者：来自OptiTROP-Lung03随机研究的结果
讲者：中山大学肿瘤防治中心 张力
局晚期非小细胞肺癌/小细胞肺癌/其他胸部肿瘤
摘要号: LBA8000
英文标题：Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816.
中文标题：CheckMate816研究中辅助纳武利尤单抗联合化疗在可切除NSCLC患者中的总生存期（OS）
讲者：Patrick M. Forde, MD, PhD | Trinity St. James's Cancer Institute, Trinity College Dublin
摘要号: 8001
英文标题：Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC: NeoADAURA.
中文标题：新辅助奥希替尼±化疗 vs 单独化疗在可切除EGFR突变NSCLC中的应用：NeoADAURA 研究
讲者：Jamie E. Chaft, MD, FASCO | Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College
摘要号: 8002
英文标题：Lung cancer diagnosis rates (LCDR) in lung cancer screening (LCS) and incidental pulmonary nodule (IPN) cohorts in the Mississippi Delta.
中文标题：密西西比三角洲地区肺癌筛查（LCS）和偶发性肺结节（IPN）队列中的肺癌诊断率（LCDR）
讲者：Raymond U. Osarogiagbon, MBBS, FACP, FASCO | Baptist Cancer Center, Multidisciplinary Thoracic Oncology Program
摘要号: 8003
英文标题：SWOG/NRG S1914: Randomized phase III trial of induction/consolidation atezolizumab + SBRT versus SBRT alone in high risk, early-stage NSCLC.
中文标题：SWOG/NRG S1914：高风险早期NSCLC患者中诱导 / 巩固阿替利珠单抗联合SBRT 对比单纯SBRT的III期随机临床试验
讲者：Megan Eileen Daly, MD | Department of Radiation Oncology, University of California Davis Comprehensive Cancer Center
摘要号: LBA8004
英文标题：R-ALPS: A randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of TQB2450 with or without anlotinib as maintenance treatment in patients with locally advanced and unresectable (stage III) NSCLC without progression following concurrent or sequential chemoradiotherapy.
中文标题：R-ALPS：TQB2450联合或不联合安罗替尼作为维持治疗在经同步或序贯放化疗后无进展的局部晚期不可切除（Ⅲ期）非小细胞肺癌患者中的随机、双盲、安慰剂对照、多中心Ⅲ期临床试验
讲者：中山大学肿瘤防治中心 陈明
摘要号: LBA8005
英文标题：Randomized phase II trial investigating whether atezolizumab after chemoradiotherapy (CRT) prolongs survival in limited stage (LS) small cell lung cancer (SCLC).
中文标题：一项随机II期试验，研究放化疗（CRT）后使用阿替利珠单抗是否能延长局限期（LS）小细胞肺癌（SCLC）患者的生存期
讲者：Bjorn Henning Gronberg, MD, PhD | Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology and Department of Oncology, St. Olavs Hospital
摘要号: 8006
英文标题：Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial.
中文标题：芦比替定（lurbi）联合阿替利珠单抗（atezo）作为广泛期小细胞肺癌（ES-SCLC）患者的一线（1L）维持治疗：III期IMforte试验的主要结果
讲者：Luis G. Paz-Ares, MD, PhD | Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc
摘要号: 8007
英文标题：A phase 2 dose expansion study of ZG006, a trispecific T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with advanced small cell lung cancer.
中文标题：ZG006（一种靶向CD3/DLL3/DLL3的三特异性T细胞接合器）单药治疗晚期小细胞肺癌患者的2期剂量扩展研究
讲者：上海市胸科医院 艾星浩
摘要号: LBA8008
英文标题：Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis of Ph3 DeLLphi-304.
中文标题：Tarlatamab对比化疗作为SCLC二线治疗：III期DeLLphi-304研究的主要分析
讲者：Charles M Rudin, MD, PhD | Fiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center
口头摘要速递专场（Rapid Oral Abstract Session）
局晚期非小细胞肺癌/小细胞肺癌/其他胸部肿瘤
摘要号: 8009
英文标题：Association of post-surgical MRD status with neoadjuvant ctDNA dynamics, genomic mutations, and clinical outcomes in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial.
中文标题：III期AEGEAN试验中可切除非小细胞肺癌（R-NSCLC）患者术后MRD状态与新辅助 ctDNA动态变化、基因组突变及临床结局的相关性
讲者：Martin Reck, MD, PhD | Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research
摘要号: LBA8010
英文标题：Perioperative nivolumab (NIVO) vs placebo (PBO) in patients (pts) with resectable NSCLC: updated survival and biomarker analyses from CheckMate 77T.
中文标题：CheckMate77T研究中围手术期纳武利尤单抗对比安慰剂用于可切除NSCLC患者的更新生存及生物标志物分析
讲者：Mariano Provencio, MD, PhD | Hospital Universitario Puerta de Hierro
摘要号: 8011
英文标题：ctDNA-based MRD detection in unresectable NSCLC undergoing curatively intended chemoradiotherapy and durvalumab
中文标题：基于ctDNA的MRD检测用于接受根治性放化疗联合度伐利尤单抗治疗的不可切除NSCLC患者
讲者：Aslaug Helland, MD, PhD | University of Oslo, Clinical Medicine
摘要号: 8012
英文标题：The preliminary results of a randomized phase II trial evaluating induction toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab in bulky unresectable stage III non-small-cell lung cancer (InTRist).
中文标题：一项评估特瑞普利单抗联合诱导化疗，随后同步放化疗及特瑞普利单抗巩固治疗用于巨大不可切除的Ⅲ期非小细胞肺癌的随机II期试验的初步结果
讲者：中国医学科学院北京协和医学院肿瘤医院 Yu Wang
摘要号: 8013
英文标题：Safety and efficacy of lurbinectedin plus atezolizumab as second-line treatment for advanced small-cell lung cancer: Results of the 2SMALL phase 1/2 study (NCT04253145)
中文标题：芦比替定联合阿替利珠单抗作为晚期小细胞肺癌二线治疗的安全性和有效性：Ⅰ/Ⅱ期2SMALL研究（NCT04253145）结果
讲者：Santiago Ponce Aix, MD, PhD | Hospital Universitario 12 de Octubre and Oncosur Foundation
摘要号: 8014
英文标题：Clinical and molecular characteristics of early progressors (EPs) and long-term progression-free survivors (LTPs) from the phase 3 ADRIATIC trial of consolidation durvalumab (D) vs placebo (P) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC)
中文标题：III期ADRIATIC试验中巩固度伐利尤单抗对比安慰剂用于同步放化疗（cCRT）后的LS-SCLC早期进展者（EPs）和长期无进展生存者（LTPs）的临床和分子特征
讲者：David Allen Barbie, MD | Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute
摘要号: 8015
英文标题：Alectinib as neoadjuvant treatment in potentially resectable stage III ALK-positive NSCLC: Final analysis of ALNEO phase II trial (GOIRC-01-2020-ML42316).
中文标题：阿来替尼作为潜在可切除的III期ALK阳性NSCLC的新辅助治疗：ALNEO II 期试验（GOIRC-01-2020-ML42316）最终分析
讲者：Marcello Tiseo | Department of Medicine and Surgery, University of Parma; Medical Oncology Unit, University Hospital of Parma; Gruppo Oncologico Italiano di Ricerca Clinica, GOIRC
摘要号: 8016
英文标题：Efficacy and safety of nivolumab plus ipilimumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial.
中文标题：纳武利尤单抗联合伊匹木单抗治疗经治的B3型胸腺瘤和胸腺癌患者的疗效和安全性：EORTC-ETOP NIVOTHYM II期试验结果
讲者：Nicolas Girard, MD, PhD | Institut du Thorax Curie Montsouris, Institut Curie, Paris, and UVSQ, Paris Saclay University
摘要号: 8017
英文标题：Integrin αVβ3-targeted imaging for identification of lung cancer and mapping of lymph-node metastases: A prospective, multicenter, self-controlled phase 3 trial (TRIIL study).
中文标题：整合素αVβ3靶向成像用于肺癌识别及淋巴结转移灶定位：一项前瞻性、多中心、自身对照的III期试验（TRIIL研究）
讲者：中国医学科学院北京协和医院 Rongxi Wang
转移性非小细胞肺癌
摘要号: 8512
英文标题：Telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced EGFR-mutated (MT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase 1 study.
中文标题：Telisotuzumab adizutecan（ABBV-400；Temab-A，一种靶向c-Met蛋白的ADC）治疗晚期EGFR突变（MT）非鳞状（NSQ）NSCLC患者：I期研究结果
讲者：David Ross Camidge, MD, PhD | University of Colorado Cancer Center
摘要号: 8513
英文标题：Efficacy and CNS results from a randomized subset of the phase 2 SAVANNAH study comparing savolitinib (savo) + osimertinib (osi) combination with savo + placebo (PBO).
中文标题：II期SAVANNAH研究中随机亚组的疗效及中枢神经系统（CNS）结果，赛沃替尼联合奥希替尼 vs 赛沃替尼联合安慰剂
讲者：Benjamin Philip Levy, MD, FASCO | Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicin
摘要号: 8514
英文标题：Phase 3 study of benmelstobart in combination with chemotherapy followed by sequential combination with anlotinib for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer (sq-NSCLC).
中文标题：贝莫苏拜单抗联合化疗，随后序贯联合安罗替尼一线治疗局部晚期或转移性鳞状非小细胞肺癌的3期研究
讲者：中国医学科学院肿瘤医院 石远凯
摘要号: 8515
英文标题：Plasma-guided adaptive first-line chemoimmunotherapy for non-small cell lung cancer (NSCLC).
中文标题：血浆指导的NSCLC适应性一线化疗免疫治疗
讲者：Julia K. Rotow, MD | Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute
摘要号: 8516
英文标题：Randomized trial of relevance of time-of-day of immunochemotherapy for progression-free and overall survival in patients with non-small cell lung cancer.
中文标题：非小细胞肺癌患者免疫化疗时间与无进展生存期及总生存期相关性的随机试验
讲者：湖南省肿瘤医院 张永昌
摘要号: 8517
英文标题：Hypoxia-responsive CEA CAR-T cells therapy for relapsed or refractory non-small cell lung cancer: A single-arm, open-label, phase I trial.
中文标题：缺氧反应型CEA CAR-T 细胞疗法治疗复发或难治性非小细胞肺癌：一项单臂、开放标签、Ⅰ期试验
讲者：华中科技大学同济医学院附属同济医院 魏双
摘要号: 8518
英文标题：S1900E: A phase II study examining impact of co-mutations on sotorasib for previously treated stage IV/recurrent KRAS G12C mutated (MUT) non-squamous (Non-sq) non-small cell lung cancer (NSCLC) (ECOG-ACRIN led Lung-MAP Sub-study).
中文标题：S1900E：一项II期研究评估共突变对sotorasib治疗既往接受过治疗的IV期 / 复发性 KRAS G12C突变非鳞状（Non-sq）NSCLC的影响（ECOG-ACRIN主导的Lung-MAP子研究）
讲者：Sukhmani Kaur Padda, MD | Fox Chase Cancer Center/Temple Health
摘要号: 8519
英文标题：Safety and efficacy of olomorasib + immunotherapy in first-line treatment of patients with KRAS G12C-mutant advanced NSCLC: Update from the LOXO-RAS-20001 trial.
中文标题：olomorasib联合免疫治疗用于KRAS G12C突变晚期NSCLC患者一线治疗的安全性和有效性：LOXO-RAS-20001试验更新结果
讲者：Konstantin H. Dragnev, MD | Dartmouth Cancer Center
摘要号: 8520
英文标题：Sosimerasib monotherapy in patients with previously treated KRAS G12C–mutated non-small cell lung cancer: Primary results of a phase 2 study.
中文标题：Sosimerasib单药治疗既往接受过治疗的KRAS G12C突变非小细胞肺癌患者：2期研究的主要结果
讲者：中国医学科学院肿瘤医院 王洁
临床科学研讨会（Clinical Science Symposium）
双靶点，同一目标：双特异性抗体在胸部恶性肿瘤中的潜力
摘要号: 8509
英文标题：First-in-class PD-1/IL-2 bispecific antibody IBI363 in patients (Pts) with advanced immunotherapy-treated non-small cell lung cancer (NSCLC).
中文标题：首创新药 PD-1/IL-2 双特异性抗体 IBI363 用于治疗经免疫治疗的晚期非小细胞肺癌患者
讲者：浙江大学医学院附属第一院 周建娅
摘要号: 8511
英文标题：First report of efficacy and safety results from a phase 2 trial evaluating BNT327/PM8002 plus chemotherapy (chemo) as first-line treatment (1L) in unresectable malignant mesothelioma.
中文标题：首个评估 BNT327/PM8002 联合化疗作为不可切除恶性胸膜间皮瘤一线治疗的2期试验的疗效及安全性结果报告
讲者：吉林省肿瘤医院 程颖
*本文根据目前官网信息整理汇总，如有疏漏，欢迎补充指正。
排版编辑：肿瘤资讯-TY
苏公网安备32059002004080号
